Purpose: To evaluate the regenerating potential and the mechanisms through which the autologous serum derived from plasma rich in growth factors (s-PRGF) favours corneal wound healing in vitro and in vivo. Methods: We compared the effect of various concentrations of s-PRGF versus fetal bovine serum (FBS) and control treatment in rabbit primary corneal epithelial and stromal cells and wounded rabbit corneas. Cell proliferation was measured using an enzymatic colorimetric assay. In vitro and in vivo wound-healing progression was assessed by image-analysis software. Migration and invasion were evaluated using transfilter assays. Histological structure was analysed in stained sections. Protein expression was evaluated by immunohistochemistry. Results: s-PRGF promoted the robust proliferation of epithelial cultures at any concentration, similar to FBS. Likewise, s-PRGF and FBS produced similar re-epithelialization rates in in vitro wound-healing assays. In vivo, s-PRGF treatment accelerated corneal wound healing in comparison with control treatment. This difference was significant only for 100% s-PRGF treatment in our healthy rabbit model. Histological analysis confirmed normal epithelialization in all cases. Immunohistochemistry showed a higher expression of cytokeratins 3/76 and 15, zonula occludens-1 and alpha-smooth muscle actin proteins as a function of s-PRGF concentration. Notably, keratocyte density in the anterior third of the stroma increased with increase in s-PRGF concentration, suggesting an in vivo chemotactic effect of s-PRGF on keratocytes that was further confirmed in vitro. Conclusion: s-PRGF promotes proliferation and migration and influences limbal stemness, adhesion and fibrosis during corneal healing.
Introduction
The health of the ocular surface depends on the integrity of the corneal epithelium. To maintain a healthy corneal epithelium, there must be a balance among limbal stem cell function, tear quantity and quality, eyelid anatomy and function and corneal sensitivity (Tseng & Tsubota 1997) . Altering any of these elements can lead to a corneal epithelial defect. In general, the woundhealing process is a complex mechanism characterized by haemostasis (not applicable in cornea), inflammation, cell proliferation, migration and differentiation. In cornea, tear film, aqueous humour and limbal vessels provide the factors needed for tissue regeneration (Klenkler et al. 2007 ). In addition, the corneal epithelium by itself is a rich source of cytokines with the potential to modulate wound repair (Wilson et al. 2001) . In cases of persistent corneal epithelium defects that fail to respond to standard treatments such as artificial tears and antibiotic drops, various methods to improve ocular surface tropism have been described: lateral tarsorrhaphy (Panda et al. 1999) , bandage contact lenses (Rosenthal et al. 2000) , punctual plugs (Seitz et al. 2005 ) and amniotic membrane transplantation (Kruse et al. 1999) . Treatments based on the application of specific molecules have also been evaluated: nerve growth factor (NGF; Lambiase et al. 1998) , epidermal growth factor (EGF; Pastor & Calonge 1992) , fibroblast growth factor (FGF; Tripathi et al. 1990 ), platelet-derived growth factor (PDGF; Murali et al. 1994 ) and substance P and insulin-like growth factor (IGF-1; Yamada et al. 2008) . However, the need to target various signalling pathways of wound healing demands a balanced combination of mediators. For that reason, in the treatment of injured tissue, it may be supposed that a mixture of repairing factors would be more effective than a single purified molecule (Slater et al. 1995) .
Since the late 1990s, the use of platelets as vehicles for the delivery of a balanced pool of healing factors has emerged as a fashionable therapy. Platelet-concentrated derivatives are generically called platelet-rich plasmas (PRPs). They provide supra-physiological concentrations of signalling cytokines and growth factors at the site of injury that may improve repair by various different mechanisms including the regulation of inflammation, angiogenesis, and synthesis and remodelling of new tissue (Andia & Abate 2013) . Some of these signalling molecules included in PRPs are epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), platelet-derived growth factor (PDGF), transforming growth factor-b (TGFb), tumour necrosis factor-a (TNF-a), neural growth factor (NGF). In fact, growth factors are a small subset of the thousands of other different molecules that can be found in PRP, such as cytokines, chemokines, adhesion proteins and enzymes, being the synergetic interaction among all of them the key of its beneficial effect (Klenkler & Sheardown 2004; Andia & Abate 2013; Andia & Maffulli 2013) . PRPs have already been reported to facilitate wound healing for skin defects, and burns including radio-therapy burns (Molina-Miñano et al. 2009; Pallua et al. 2010) , as well as for cosmetic, plastic, dental, orthopaedic and cardiothoracic surgery (Marx et al. 1998; Everts et al. 2006) . Drops of blood derivatives have also been described as a treatment in ophthalmology for different ocular surface disorders, including persistent epithelial defects (Anitua et al. 2015a ). These derivatives include various formulations, such as autologous serum (Tsubota et al. 1999a,b) , serum from fetal umbilical cord (Vajpayee et al. 2003) , plasma rich in platelets (Ali o et al. 2007a) and serum derived from plasma rich in growth factors (s-PRGF; L opez- Plandolit et al. 2010) . In addition, these preparations have been used as an alternative treatment for severe dry eye syndrome (Tsubota et al. 1999a,b; Ali o et al. 2007b; L opez-Plandolit et al. 2011) , the epithelialization after LASIK (Javaloy et al. 2013) and as an alternative to close corneal perforations by using it as a solid PRP .
One of these PRPs, PRGF, was originally developed to speed the healing of traumatic and maxillary defects (Anitua 1999) . Recently, our group has introduced its use in ophthalmology for the treatment of persistent epithelial defects and dry eye syndrome (L opezPlandolit et al. 2010 (L opezPlandolit et al. , 2011 . PRGF has a moderate platelet concentration, and this has been associated with optimal biological benefits (Anitua et al. 2015a) . Additionally, its leucocyte content has been eliminated to avoid the pro-inflammatory effects of proteases and acid hydrolases contained in white blood cells (Anitua et al. 2015b ). Hence, this type of PRP can be classified as pure platelet-rich plasma or P-PRP according to the classification proposed by Dohan Ehrenfest et al. (2009) . In administering PRGF for the first time as eye drops in the ophthalmological context, our group slightly modified the method for manufacturing this derivative (compared to the original protocol), by using the whole volume over the buffy coat and prolonging the coagulation time until complete clot retraction was achieved. Thus, we obtained serum derived from plasma rich in growth factors (s-PRGF; L opez-Plandolit et al. 2010) .
In this study, we explored the effect of different concentrations of s-PRGF on the in vitro proliferation and re-epithelialization processes in rabbit primary corneal epithelial (RPCE) cultures, as well as in the in vivo corneal re-epithelialization in a rabbit animal model. A novelty of this work lies in that we have analysed the effect of s-PRGF compared to that of fetal bovine serum (FBS) on the transfilter migration and invasion ability of primary cultures of rabbit corneal stromal cells (keratocytes) and we have investigated in vivo the chemotactic effect of s-PRGF on keratocytes. To achieve this, we first optimized the method for obtaining s-PRGF from rabbit blood, this being different in various respects to that which we first described for human blood for use in ophthalmology (L opez-Plandolit et al. 2010 ). To our knowledge, this is the first study comparing in parallel various culture media containing different concentrations of s-PRGF, with each other and with 10% FBS, the latter being the usual supplement of culture medium for human cell culture accepted by scientific community in spite of his xenogeneic origin. The aim of this comparison was to assess the regenerative potential of s-PRGF, using the known capability of xenogeneic FBS to stimulate the growth of cells and tissues as a reference. Regarding in vivo studies, some authors have used human blood derivatives in animal corneal defects (Anitua et al. 2013) , demonstrating their safety, but this xenogeneic use does not guarantee the effectiveness of the product. In this study, we have employed rabbit serum to assess rabbit corneal wound healing, in an autologous manner, which demonstrates the efficacy of this blood derivative in the rabbit animal model. In addition, most articles on ophthalmic clinical use of s-PRGF report descriptive non-controlled studies. This study provides data concerning the effect of autologous s-PRGF on corneal wound healing under controlled conditions in an animal model (rabbit). The findings obtained could justify the implementation of further controlled clinical trials. Finally, this work suggests a global effect of s-PRGF in corneal regeneration, because it shows that s-PRGF promotes reepithelialization in the wounded area while influences the behaviour of stem cells in the limbal area.
Materials and Methods

Ethics statement
This project was performed in accordance with the ARVO Statement for To obtain RPCE cultures, the central corneal buttons were removed from eyes of three 2.0-2.5 kg female New Zealand rabbits, keeping the limbal zone intact, and processed as previously described (Freire et al. 2014 ). The cells obtained were cultured at 37°C under 5% CO 2 in DMEM: Ham 0 s F12 mix with 2 mM L-glutamine (Lonza, Verviers, Belgium) and 1% penicillin-streptomycin, together with 10% fetal bovine serum (FBS; Lonza). This culture medium was also supplemented with: 10 ng/ml EGF (Sigma, St. Louis, MO, USA), 5 lg/ ml insulin (Sigma) and 0.1 lg/ml cholera toxin (Gentaur Molecular Products, Brussels, Belgium).
Isolation and expansion of rabbit primary keratocytes
Primary cultures of keratocytes were obtained from the stroma of the previously removed New Zealand rabbit corneas. Specifically, the corneal stroma was obtained by treatment of the whole cornea with 25 UI/ml dispase II for 16 hr at 4°C followed by smooth manual scrapping off of the epithelium. Then, the stroma was digested with 1 mg/ml type I collagenase (Sigma) for 1.5 hr at 37°C. The cells obtained were cultured at 37°C under 5% CO 2 in keratinocyte-SFM (low-calcium and serum-free) culture medium (Gibco, Invitrogen, Carlsbad, CA, USA), to avoid the differentiation of cells into fibroblasts or myofibroblasts ).
s-PRGF preparation
To obtain s-PRGF, 5-10 ml of blood was collected by puncture of the central artery of the rabbit ear in tubes with 3.8% sodium citrate as anticoagulant (BD Biosciences, Franklin Lakes, NJ, USA). Blood was centrifuged for 8 min at 650 g. Following collection of the complete supernatant fraction above the buffy coat, clot formation was induced by adding calcium chloride. After incubation of the samples for 1 hr at 36°C, the fibrin clot was retracted and removed; the remaining fraction was the rabbit s-PRGF (Freire et al. 2014) .
For in vitro assays, the complement factors of s-PRGF were inactivated at 56°C for 30 min to avoid inflammatory reactions. Subsequently, we pooled samples from several individuals to obtain representative blood preparations that provided reproducible results and minimized interindividual variability. For in vivo assays, we used autologous preparations. All preparations were stored at À20°C until use.
Cell proliferation
The effect of s-PRGF on the proliferation of RPCE cultures was measured at several dilutions (10, 20 and 50%) and time-points (24, 48 and 72 hr). Proliferation was described in terms of proliferation rate AE SD of viable cells with respect to viable cells just before exposure to blood derivatives (t = 0 hr).
This was measured using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide or MTT assay (Sigma-Aldrich), as previously described (Freire et al. 2012) . Optical densities at 540 nm were determined using a microplate reader (ELx800 Microplate Reader, BioTekÒ Instruments, Winooski, VT, USA). All experiments were performed in quadruplicate and repeated in three biological replicates of RPCE cultures (n = 12).
In vitro wound-healing assays
These experiments were performed as previously described (Freire et al. 2014) . RPCE cultures were maintained with culture medium containing supplements and 10% FBS (n = 28), 50% s-PRGF (n = 28) or 1% BSA (n = 15) as a control. Areas from which cells had been scraped away were photographed every 12 hr with an Eclipse TS 100 phase-contrast microscope (Nikon, Tokyo, Japan), and images were acquired with ProgRes CapturePro 2.6 software (Jenoptik, Jena, Germany). The size of the denuded areas was quantified using ImageJ software (developed by Wayne Rasband at the Research Services Branch, National Institute of Mental Health, Bethesda, MD, USA). The closure rate was described in terms of the mean remaining denuded area AE standard deviation (SD) in mm 2 . All experiments were performed at least in quintuplicate (five wells) and repeated in three biological replicates of RPCE cultures.
In vitro migration and invasion assays
We performed transfilter migration and Matrigel transfilter invasion assays to analyse the capability of s-PRGF to induce chemotaxis or invasion in rabbit primary stromal keratocytes.
For migration experiments, we used 24 transwell plates with 8-lm membrane pore size (BD Biosciences). We seeded 3 9 10 5 cells in every insert and repeated the following treatments in triplicate and repeated in three biological replicates: (i) DMEM:F12 with 1% BSA as control medium in the lower well and DMEM:F12 with 1% FBS in the upper well (n = 9); (ii) DMEM:F12 with 10% FBS in the lower well and DMEM:F12 with 1% FBS in the upper well (n = 9); (iii) DMEM:F12 with 50% s-PRGF in the lower well and DMEM:F12 with 1% s-PRGF in the upper well (n = 9); and (iv) DMEM: F12 with 80% s-PRGF in the lower well and DMEM:F12 with 1% s-PRGF in the upper well (n = 9). For invasion experiments, we reproduced the same treatments, cell number and culture conditions as used for migration assays using Matrigel-coated inserts (BD Biosciences).
After incubation for 7 hr for migration and 24 h for invasion in a 37°C with 5% CO 2 atmosphere, inserts and wells were washed three times with phosphate-buffered saline. Cotton swabs were used to carefully remove cells on the upper surface of the membrane. Both wells and membranes were fixed in methanol for 10 min. Finally, they were rinsed three times with phosphate-buffered saline, being stained with 1 lg/ml DAPI in the second rinsing. Membranes and wells were photographed with an FV500 Confocal microscope (Olympus, Tokyo, Japan). Cell nuclei stained with DAPI in membranes and wells were counted using ImageJ software.
Rabbit corneal re-epithelialization assays
Fourteen adult 2.0-2.5 kg female New Zealand white rabbits were included in the study. Since the arrival of animals to our institution's facilities until they were humanly euthanized once the experimental study was finished, rabbits were under diary observation to assess their welfare. Initially, each rabbit underwent surgery in the right eye, and the left eye was then operated on 2-3 weeks after the right eye had recovered. The surgery was performed as previously described (Freire et al. 2014) . Postoperatively, until the epithelial closure was complete (up to a maximum of a week), every rabbit eye was treated with a topical dexamethasone and chloramphenicol ointment (DeicolÒ ophthalmic ointment, Alcon laboratories, Barcelona, Spain) for anti-inflammatory and antibiotic effects, and topical diclofenac drops (VoltarenÒ drops, Allergan, Inc., Irvine, CA, USA) for analgesia, twice a day. In addition, the eyes were treated topically four times a day with one of the treatments under study. For this, the rabbits were randomized for each surgical intervention into one of the following four groups: Group 1) 20% s-PRGF drops (n = 9); Group 2) 50% s-PRGF drops (n = 9); Group 3) 100% s-PRGF drops (n = 5) or Group 4) artificial tears containing povidone (Oculotect, Alcon) as the control group (n = 5). S-PRGF was diluted in balanced saline solution (BSSÒ Alcon, Fort Worth, TX, USA) when necessary. In addition, the order in which the animals in the different experimental groups were treated was randomized.
To assess the size of the residual epithelial defect, the eyes were photographed with and without fluorescein once a day, with a ruler placed in the same plane as the ocular surface, and always at the same time of day. Wounded areas were measured using ImageJ software, and results were expressed as mean wound area AE SD in mm 2 . Rabbit eyes were also examined for signs of corneal inflammation and neovascularization.
Histochemical evaluation
After both eyes of each animal had been operated on and followed up, that is, 7 days after surgery for left eyes and 30 days after surgery for right eyes (7 days of treatment and 3 weeks more without treatment for right eyes), corneas were removed, fixed in 4% paraformaldehyde, included in paraffin and cut into 4-lm tissue sections. Some tissue sections were processed for haematoxylin-eosin staining. Stained sections were observed with a phasecontrast microscope (Nikon Eclipse TS 100), and images were acquired with the PROGRES CAPTUREPRO 2.6 software. We evaluated the structural integrity and histological characteristics of the cornea as well as the regeneration of the epithelium and cell infiltration. We also counted under the 209 objective lens the number of keratocytes in three random fields of the anterior third of the stroma in haematoxylineosin sections from three rabbits under each treatment (n = 9 for each treatment).
Some other corneal tissue sections were prepared for immunofluorescent staining according to conventional protocols. Briefly, sections were treated with the heat-induced antigen retrieval solution Tris:EDTA pH 9.0 for 40 min at 96°C. Then, sections were permeabilized with phosphate-buffered saline solution containing 0.5% Triton-X-100 (Sigma) for 10 min and preincubated with phosphate-buffered saline containing 5% BSA and 10% SBF for an additional hour to minimize non-specific signals. Then, sections were incubated at 4°C overnight with the following primary antibodies at the respective dilutions: mouse anti-keratin K3/K76 (1:20, Millipore, Temecula, CA, USA), mouse anti-cytokeratin K15 (1:50, Santa Cruz, Dallas, TX, USA), goat anti-ZO1 tight junction protein antibody C-terminal (1:20, Abcam, Cambridge, MA, USA), mouse anti-alpha-smooth muscle actin (a-SMA; 1:20, Abcam). After the sections were washed with phosphatebuffered saline, the samples were incubated with secondary antibodies for 1 hr at room temperature and protected from light. We used the following secondary antibodies (1:1000, Invitrogen): goat anti-mouse IgG1 Alexa Fluor 568 conjugate, goat antimouse IgG2a Alexa Fluor 488 conjugate, donkey anti-goat IgG Alexa Fluor 568 conjugate and goat anti-mouse IgG2a AlexaFluor 488 conjugate. The DNA-specific dye DAPI (1 lg/ml, Sigma) was used to detect nuclei. Finally, the sections were mounted with Fluoromount-g (Electron Microscopy Sciences, Hatfield, PA, USA) and photographed with a fluorescence microscope (Zeiss, G€ ottingen, Germany).
Statistical analysis
SPSS Statistics version 18 (IBM, Chicago, IL, USA) was used to calculate means and standard deviations and to perform statistical tests. As the variables did not follow a Gaussian distribution, we used the nonparametric Mann-Whitney U-test to compare medians. The Kaplan-Meier estimator was used to study the number of days that corneal epithelial defects took to heal completely. For the statistical comparison of qualitative parameters, a chi-squared test was performed. p-values <0.05 were considered significant differences.
Results
In vitro proliferation and wound-healing assays in RPCE cultures
We studied cell proliferation in RPCE cultures under treatment with different concentrations (10, 20 and 50%) of s-PRGF. We found that all concentrations of s-PRGF produced a time-dependent proliferation pattern (Fig. 1A) . There was not, however, a statistically significant dose-dependent association. We only observed a weak trend to a higher proliferation rate with the 50% s-PRGF treatment compared to that with concentrations of 10 or 20% (Fig. 1B) . Conversely, the proliferation rate was significantly higher with all concentrations of s-PRGF than with 1% BSA at 48 and 72 hr. Notably, we found no statistically significant differences in the cell proliferation rate of cultures treated with 10% FBS compared to 10, 20 or 50% of s-PRGF at any time-points.
We performed scratch wound-healing assays on RPCE cultures to determine the ability of s-PRGF to promote in vitro migration and re-epithelialization. After scraping off rounded areas in cell culture monolayers, we treated them with s-PRGF, FBS and BSA as a control treatment. As a 50% dilution of s-PRGF appeared to have better results in the proliferation assay, we chose this dilution for s-PRGF for these experiments. We found that s-PRGF accelerated the recovery of the monolayer with respect to that in controls (1% BSA; Fig. 1C ), the differences being statistically significant at all time-points.
Although FBS is not usually used for healing assays, as it is the usual supplement for the maintaining and proliferation of cell cultures, we included it in the wound-healing assay. There were no significant differences between using s-PRGF and FBS in the closure rate of the denuded area.
In vivo corneal re-epithelialization assay in a rabbit animal model
We performed an in vivo assay to study corneal re-epithelialization in a rabbit model. To provide evidence to support its potential use for human corneal epithelial defects, we assessed both the efficacy and the safety of s-PRGF. To perform the experiment, eyes with surgically induced epithelial ulcers were treated with s-PRGF at 20, 50 or 100% or with artificial tears as a control treatment.
We did not observe any adverse events, such as corneal inflammation or neovascularization, in any eye of any study group, either during the healing process or when the complete regeneration of the wound was achieved ( Fig. 2A) . All animals were healthy and gained weight progressively.
The results showed that 100% s-PRGF promoted markedly faster corneal wound healing than the other treatments (Table 1) . Notably, the corneal epithelium was completely re-epithelialized in most of the eyes treated with 100% s-PRGF by Day 4, and in all eyes by Day 5 after surgery, showing a mean time to complete closure of the epithelial defect of 4.8 AE 0.45 days (Fig. 2B) . Furthermore, this mean was significantly different with respect to all the other closure times, which were 5.8 AE 3.50 days for eyes treated with 20% s-PRGF, 5.8 AE 3.47 days for those treated with 50% s-PRGF and 6.2 AE 1.30 days for eyes under the control treatment.
Focusing on 5 days after surgery, all of the corneal defects under 100% s-PRGF treatment had already healed (5/5), while only 30-40% of them had re-epithelialized in the 20% s-PRGF and 50% s-PRGF groups (3-4/9) or in the control group (2/5; Fig. 2C ). Finally, we did not find any significant differences when comparing control, 20% and 50% s-PRGF groups at any time during the wound-healing process.
Analysis of haematoxylin-eosin sections of the rabbit central corneas after healing showed that, by the end of the study, the corneal epithelium had successfully healed in all rabbits. Epithelial regeneration was normal showing a multistratified non-keratinized and well-organized epithelium (Fig. 3) . Focal hyperplasia of one to two layers of epithelial cells was observed in all re-epithelialized corneas when compared to the histological sections of a healthy cornea (data not shown). No alterations were observed in the endothelium. Stromal depth was maintained across the whole cornea, with healthy collagen fibres.
Effects of s-PRGF on stromal cells
We found that in rabbits which had been euthanized 7 days after surgery, keratocytes had disappeared in the anterior third of the stroma of eyes under the control treatment (Fig. 3) . Interestingly, the abundance of keratocytes increased with s-PRGF concentration, becoming progressively higher in eyes treated with 20, 50 and 100% s-PRGF. Thus, the keratocyte number was 1.5 AE 1.64 for eyes under the control treatment, 2.7 AE 1.75 for eyes treated with 20% s-PRGF, 7.0 AE 4.34 for those treated with 50% s-PRGF and 34.7 AE 2.31 for eyes treated with 100% s-PRGF. What is more, only eyes treated with 100% s-PRGF had keratocytes through the full depth of the stroma. We found statistically significant differences in the number of keratocytes in eyes treated with 50% and 100% s-PRGF with respect to control eyes (p = 0.020 and p = 0.019, respectively, Mann-Whitney U-test). Only 100% s-PRGF treatment produced significant differences in the number of keratocytes compared to all other treatments, including 50% s-PRGF (p = 0.020). In rabbits euthanized 1 month after surgery, keratocytes were found across the entire stroma, even in eyes that had received the control treatment. BSA and all other treatments at 48 and 72 hr. No differences were found between any % of s-PRGF and 10% FBS. (C) Percentage of re-epithelialized area of RPCE cultures after 12 hr of culture incubation with 50% s-PRGF, 10% FBS and 1% BSA as the control treatment. s-PRGF and FBS both stimulated the migration of RPCE cells compared to the control treatment, with no significant differences between them. *Statistically significant differences with respect to 1% BSA (p ≤ 0.05, Mann-Whitney U-test). N/S: not significant.
To further confirm a possible promotion of chemotaxis of rabbit stromal keratocytes by s-PRGF, we developed in vitro transwell migration and invasion assays. Considering that these assays last up to 24 hr, and with the aim of using as high a concentration of s-PRGF as possible, we compared the chemotactic potential of 50 and 80% s-PRGF with that of 10% FBS and of 1% BSA (control treatment). Migration rates were found to be highest with the two s-PRGF concentrations (Table 2) , being significantly higher than those with FBS or BSA. Moreover, the stimulation of keratocyte migration by 50% s-PRGF was significantly stronger than that observed with 80% s-PRGF. Conversely, no matter the medium used, no differences were found in the invasion capability of keratocytes. Percentage of the initial area of induced corneal epithelial defect that had healed at different numbers of days after surgery using treatments with increasing topical concentrations of s-PRGF drops or artificial tears. Eyes treated with 100% s-PRGF heal much faster than those receiving any of the other treatments. Statistically significant differences (p < 0.05, Mann-Whitney U-test) with respect to the control treatment (*), 20% s-PRGF ( † ) or 50% s-PRGF ( ‡ ). (C) Percentage of resolved epithelial defects in rabbit corneas by 5 days after surgery. All eyes under 100% s-PRGF treatment had already healed, while only 30-40% had re-epithelialized in the 20% s-PRGF, 50% s-PRGF and control groups. *Statistically significant differences (p < 0.05, v 2 test) with respect to all other treatments.
s-PRGF influences the differentiation phenotype, adhesion property and fibrosis
To assess the mechanisms through which the autologous s-PRGF favours corneal wound healing, we used immunohistochemistry techniques to analyse rabbit corneas after the epithelial defect had healed. Figures 4 and 5 showed an increase in the number of cell layers of the epithelium stained for the cytokeratin K-3/76 and the tight junction protein ZO-1, respectively, as well as in the intensity of staining, as a function of s-PRGF concentration and the time passed since surgery. Staining was especially evident at 30 days after surgery in eyes that had received the 100% s-PRGF treatment. When we analysed the corneal limbus, where the epithelial stem/progenitor cells reside, by detecting the putative stem cell marker K-15 we observed increase in positive staining as the s-PRGF concentration increased. We found especially relevant the presence of prominent clusters of K-15 positive undifferentiated cells in the basal limbal epithelium of eyes under 100% s-PRGF treatment at Day 30 after surgery (Fig. 6) . Finally, at Day seven after surgery, a-SMA staining of stromal cells' cytoplasm was clearly detected only in corneas that had received the 100% s-PRGF treatment. At Day 30 after surgery (3 weeks after the end of treatment of rabbit corneas), a-SMA staining of corneas treated with non-diluted s-PRGF diminished markedly, remaining only a slightly positive expression (Fig. 7) .
Discussion
In recent years, PRP therapies have become widely used in ophthalmology, being considered an autologous source of growth factors and signalling molecules ). Their use is based on the premise that the platelets contained in PRPs constitute a reservoir of critical growth factors that, once released, modulate a range of biological processes including inflammation, Fig. 3 . Haematoxylin-and-eosin-stained histological sections of the rabbit central corneas after healing. Central corneas of rabbit eyes treated with various topical concentrations of s-PRGF drops or artificial tears were obtained after healing of the epithelial defect. Corneas were processed 7 days after surgery (larger micrographs, scale bar: 50 lm), or at 30 days (upper right squares, scale bar: 25 lm). Complete regeneration with normal histology of the epithelium is observed in all corneas. When euthanasia was performed 7 days after surgery, the number of keratocytes in the anterior third of the stroma was related to the % of s-PRGF used. At 30 days, no matter the treatment used, keratocytes occupied the whole stroma. angiogenesis, cell proliferation, migration, differentiation and extracellular matrix synthesis. In addition, it has also been described that the concentration of growth factors is higher when platelets are activated ).
In the PRP used in this study, s-PRGF, white blood cells are excluded because they could exacerbate tissue damage via several mechanisms. For instance, leucocytes secrete pro-inflammatory cytokines, such as tumour necrosis factor-a, interferon-c, interleukin-6 and interleukin-1b, that cause matrix destruction through the production of matrix metalloproteinase-1, metalloproteinase-3 and metalloproteinase-13 (Anitua et al. 2015b ). It may be for this reason that s-PRGF is very well tolerated (L opez-Plandolit et al. 2010 (L opez-Plandolit et al. , 2011 .
Our group was the first to employ s-PRGF in ophthalmology (L opezPlandolit et al. 2010), as well as to adapt its manufacture to the rabbit model. Although the fraction immediately above the buffy coat (fraction F3) is the one richest in platelets, our group has successfully been employing the whole fraction over the buffy coat for the treatment of some ocular surface pathologies (L opez-Plandolit et al. 2010 (L opez-Plandolit et al. , 2011 . We believe that this point is really important as the fraction next to the buffy coat is quite small and it would be necessary to obtain a great deal of blood from the patient in the case of chronic treatments. In relation to this, a comparative in vitro study has shown agreement with our results demonstrating the same effectiveness when F3 (663 000 platelets/ll) or all the supernatant (481 000 platelets/ll) were used to manufacture s-PRGF, in terms of proliferation, migration and inhibition of differentiation of stromal keratocytes (Anitua et al. 2011) . Indeed, intermediate concentrations of platelets about 300-600% above baseline (503 000-1 729 000 platelets/ll PRP) are necessary to achieve bone regeneration (Marx et al. 1998; Weibrich et al. 2004 ). However, highly concentrated platelet preparations have an inhibitory influence on osteoblast activity, probably due to the threshold dose of some inflammatory molecules having been exceeded, which could produce inhibitory and/or cytotoxic effects (Weibrich et al. 2004) .
We, as well as other authors, have found that human corneal epithelial (HCE) cells promote proliferation after treatment with s-PRGF or other blood derivatives Freire et al. 2012; Anitua et al. 2013) . Now, we have demonstrated the outstanding capability of s-PRGF to stimulate cell proliferation in primary epithelial cultures from rabbit cornea. Our findings indicate that cell migration under s-PRGF treatment in primary rabbit cultures was faster than that observed in HCE cells (Freire et al. 2014) . In primary cultures, this effect is not dose dependent, showing no significant differences compared to any s-PRGF concentration tested or, what it is more striking, compared to 10% FBS. This finding suggests that the culture of primary epithelial cells with s-PRGF could be a valuable alternative to FBS, avoiding the use of this xenogeneic product for cell expansion in cell therapy.
Surprisingly, s-PRGF and 10% FBS are similar in their capacity to promote the re-epithelialization of RPCE cells in vitro. Cell-denuded areas in both groups were almost closed in the first 12 hr after cell scraping. We also found, in rabbit eyes, a trend to a faster rate of corneal epithelial wound healing with increasing concentrations of s-PRGF, it only being significantly faster when non-diluted s-PRGF was used. Some other results from our group, in which different blood derivatives were compared, show significantly faster re-epithelialization of rabbit corneas with s-PRGF than other treatments (including autologous serum), especially in the first few days of wound healing (Freire et al. 2014) . Consistently, other studies have already demonstrated that, in the first days of treatment in healthy rabbits, skin defects heal much faster with PRGF as compared to control treatment (Molina-Miñano et al. 2009 ).
On the other hand, we did not find significant differences in corneal epithelialization of healthy rabbits when using artificial tears compared to 20 or 50% s-PRGF drops. Other authors have also concluded that diluted blood derivatives have no significant effects on corneal wound healing (Shahriari et al. 2008) . We believe that this could well be due to an intact neural pathway in our healthy rabbits and that, hence, despite a trend to faster re-epithelialization, 20 or 50% s-PRGF is insufficient to accelerate the closure of the ulcer in a statistically significant way with respect to controls. In pathological cases of neurotrophic ulcers, we consider that even low concentrations of s-PRGF could significantly accelerate epithelial healing compared to control treatments. In fact, we have demonstrated that the application of 50% s-PRGF drops is effective as a treatment for the re-establishment of the corneal epithelial surface in patients with persistent epithelial defects that did not respond to other treatments (L opez-Plandolit et al. 2010) . Nevertheless, we currently believe that, even in patients with damaged neural pathways in which the use of 50% s-PRGF is effective, 100% s-PRGF would be the optimal concentration to use, as it contains higher concentration of neurotrophic and epithelium-maintaining factors for the improvement of corneal sensitivity (Matsumoto et al. 2004; L opez-Plandolit et al. 2010) .
Our histological analysis demonstrated correct re-epithelialization in all cases 1 month after surgery. However, we did find differences in keratocyte distribution in the stromal layers as a function of s-PRGF concentration and the time passed since surgery. Specifically, when corneas were processed 7 days after surgery, the keratocyte population in superficial layers of the stroma was directly correlated with the concentration of s-PRGF used; this parameter was normal only when 100% s-PRGF was applied. When corneas were processed 1 month after surgery, regardless of the s-PRGF concentration used, the whole stroma was filled with keratocytes. Physiologically, it has been described that after debridement of corneal epithelium, keratocytes next to the wound begin to fragment and undergo cell death, creating a narrow acellular zone (Fini & Stramer 2005) . The adjacent keratocytes become activated and progress to mitosis; cells begin to migrate towards the damaged area within 24 hr, arriving at the wound in 48 hr with typical fibroblast morphology (Zieske et al. 2001; Fini & Stramer 2005) . There, activated fibroblasts secrete various different molecules that restructure the extracellular matrix and support the migration and adhesion of epithelial cells (Fini & Stramer 2005) . We, in agreement with other authors (Anitua et al. 2015c) , have demonstrated by in vitro chemotaxis assays that s-PRGF has a higher keratocyte chemo-attractant capability than FBS or the control treatment. It has also been described that the addition of fetal calf serum to in vitro cultured keratocytes initiates their activation and entry into the cell cycle, with a phenotype change very similar to that of fibroblasts. (Fini & Stramer 2005) . Our immunohistochemical findings involving a-SMA, a protein associated with activated fibroblasts and myofibroblasts (Wilson 2012) , showed positive cells in the anterior stroma of corneas treated with 100% s-PRGF. Moreover, the corneas under nondiluted s-PRGF treatment were the only ones that had cells through the full depth of the stroma, including its anterior third. These results are consistent with the hypothesis that epithelialstromal interactions are important in the development of corneal myofibroblasts (Wilson 2012 ). In our experiments, a-SMA positive staining was very slight at Day 30 in 100% s-PRGFtreated corneas (these corneas had been treated for 7 days and then maintained with no treatment for 3 weeks more before their collection and analysis). Activation and differentiation of keratocytes into myofibroblasts are physiological events in corneal wound healing. Myofibroblasts secrete large quantities of extracellular matrix and exert contraction properties, which may serve a tissue regenerative function that allows myofibroblasts to participate in wound matrix organization and wound contraction (Wilson 2012) . However, the opaque extracellular matrix laid down by myofibroblasts often contributes to stromal opacity in the transparent cornea, and must be reabsorbed by keratocytes to restore normal transparency and avoid corneal haze. Considering that a-SMA expression decreases in a few weeks after finishing non-diluted s-PRGF treatment, this PRP seems to be a very desirable product for the treatment of corneal epithelial defects. This PRP promotes a rapid regenerative response and seems to prevent scar formation in the cornea, because no opacity in the rabbit corneas has been found when using the slit-lamp; H-E sections have shown normal and well-structured tissue and a-SMA expression decreases very rapidly after treatment is ended.
Proliferation, migration and differentiation of keratocytes are known to be mediated by several growth factors that are present in s-PRGF, including TGF, PDGF and FGF (Andresen et al. 1997) . Indeed, there is a high content of PDGF in s-PRGF, the concentration being 10-fold higher than in tear film (Vesaluoma et al. 1997) . In vitro, 80% s-PRGF induced chemotaxis less strongly than 50% s-PRGF. This is consistent with the findings of other authors that the strongest migration effect on NIH3T3 fibroblasts was obtained with a moderate concentration of PDGF, the effect decreasing with higher concentrations (De Donatis et al. 2008) . This point together with the presence of an excess of inflammatory molecules that could produce inhibitory and cytotoxic effects in highly concentrated platelet preparations (Weibrich et al. 2004) could be the reason for the optimal effectiveness of moderately concentrated blood derivatives to promote in vitro chemotaxis. In vivo, this issue is not relevant as, even if non-diluted blood derivatives were to be used as eye drops, they would become diluted with tear film on the ocular surface.
In the wound-healing process, corneal epithelial stem cells located in the basal limbus provide differentiated cells for reconstructing the epithelium (Park et al. 2006; Kameishi et al. 2015) . Using the K-15 antibody, which is a marker for limbal progenitor phenotype (Yoshida et al. 2006) , we have found increasing staining as the s-PRGF concentration increases and larger clusters of stem/ progenitor cells in corneas treated with non-diluted s-PRGF. This result shows that the effect of s-PRGF is not restricted to the wound area, but effectively extends to cells in the eye periphery to provide an integral response and the resolution of the epithelial defect. Thus, s-PRGF seems to be able to stimulate proliferation of limbal stem/ progenitor cells, at the same time that maintains their stemness, supporting the re-epithelialization process. Similar results have been described for satellite cells, the tissue-specific stem cells that maintain the regenerative potential of skeletal muscle (Li et al. 2013) , as well as for some other stem/progenitor cells from mesenchymal origin (Andia & Abate 2015) .
Those cells that differentiate from progenitor cells express markers of differentiated corneal epithelial cells such as cytokeratin 3 and 12 (Secker & Daniels 2009 ). Cytokeratin K 3/76 and the cell junction-related protein zonula occludens-1 ZO-1 were found more abundantly in epithelia of the corneas treated with higher concentrations of s-PRGF. Both proteins are characteristic of mature epithelial cells (Wu et al. 2014 ). The K3 is present in all layers of the corneal epithelium and the suprabasal layers of the limbal epithelium in normal corneas. The ZO-1 protein is one of the key organizational proteins at tight junctions. These cell junctions provide intercellular adhesion properties and barrier function to the corneal epithelium (Wu et al. 2014) . Our results suggest that s-PRGF promotes the differentiation of corneal epithelial cells, creating a mature and specialized corneal epithelium and accelerating establishment of the barrier function that had been lost during corneal injury.
To sum up, we conducted a series of experiments with the blood derivative rich in growth factors s-PRGF. Because of its content and previous evidences, the use of s-PRGF could be considered particularly suitable for faster epithelial wound healing and stromal injury repair. Our results show that s-PRGF accelerates the usual mechanisms implicated in re-epithelialization, including epithelial cell proliferation, migration, adhesion and differentiation into mature and specialized epithelial cells, rapidly restoring the barrier function of the epithelium. It also promotes migration and activation of stromal cells, but avoiding scar formation. Interestingly, s-PRGF maintains the stemness properties of limbal stem/progenitor cells, while it stimulates them to proliferate and differentiate to support re-epithelialization (Fig. 8 ). All these data may explain the beneficial use observed for s-PRGF in clinical applications.
As a practical approach, it is clear that 100% is the optimal concentration of autologous s-PRGF to obtain significant benefits in corneal wound healing in healthy rabbit eyes. Notably, no toxic effect was observed in the in vivo assay, probably due to dilution of 100% s-PRGF with tears. As a consequence, we suggest using the nondiluted concentration for the clinical use of s-PRGF and maybe some other blood derivatives. Further, this study demonstrates that qid dosage is sufficient to accelerate re-epithelialization with no toxicity. However, further experiments are required to determine whether there is any dosage above which this treatment could have toxic effects on the corneal epithelium, before increasing the dosage in patients. The optimal dose of s-PRGF and the effectiveness of such treatment in neurotrophic cases remain to be determined. We believe that, even in neurotrophic cases, it is likely that stronger effects are achieved with higher concentrations and frequencies of s-PRGF application. In relation to this, non-diluted autologous s-PRGF has shown positive effects on both epithelial and stromal cells, facilitating the improvement of corneal repair without toxicity.
